Latest Articlesddd

AstraZeneca Product Trugap+Abiraterone and Androgen Deprivation Therapy Improved Primary Endpoint of Radiographic PFS in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

November 27, 2024 0

AstraZeneca in the NEWS AstraZeneca (AZN) Phase III trial CAPItello-281, which combines Truqap (capivasertib), abiraterone, and …

The U.S. FDA Approved BridgeBio Pharma Product Attruby to Treat Adults with ATTR-CM to Reduce Cardiovascular Death and Hospitalization

November 25, 2024 0

BridgeBio Pharma in the NEWS BridgeBio Pharma (BBIO) focused on genetic diseases, announced that the United …

Viking Therapeutics Presented Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

November 20, 2024 0

Viking Therapeutics Announcement On Nov. 19, 2024, Viking Therapeutics, Inc. (VKTX) announced that the final results …

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

November 19, 2024 0

Biogen & UCB Announcement Today, November 19, 2024, UCB (Euronext Brussels: (UCB) and Biogen (BIIB) presented …

Intellia Announces First Clinical Evidence from Phase 1 Study That an In Vivo CRISPR/Cas9-Based Gene Editing Therapy May Favorably Impact Disease Progression in Amyloidosis

November 19, 2024 0

Intellia Therapeutics Announcement On Nov. 16, 2024,  Intellia Therapeutics (NTLA), a clinical-stage gene editing company focused …

Adaptimmune’s Lete-cel Achieves Primary Endpoint in Pivotal Trial Treating Advanced Sarcomas and Other Solid Cancers

November 15, 2024 0

Adaptimmune Therapeutics Announcement Today, November 13, 2024, Adaptimmune Therapeutics plc (ADAP), a company working to redefine …

PTC Therapeutics: U.S. FDA Approved a First-Time Gene Therapy Administered directly into the Brain to Treat Children and Adults

November 14, 2024 0

PTC Therapeutics Announcement Today, November 13, 2024, PTC Therapeutics, Inc. (PTCT) announced that the U.S. FDA accelerated …

Altimmune Third Quarter 2024 Financial Results and Provides Business Update  

November 13, 2024 0

Altimmune Third Quarter Financial Results Yesterday, October 12, 2024, Altimmune (ALT) announced financial results for the …

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

November 12, 2024 0

BioStem Technologies Third Quarter 2024 Report Today, November 12, 2024, BioStem Technologies (BSEM), a leading MedTech …

InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update 

November 12, 2024 0

InflaRX  In March 2024, InflaRx Biopharmaceutical (IFRX) announced that it will pursue two initial immuno-dermatology indications …

Gilead Sciences 3rd Quarter Financial Results

November 7, 2024 0

From Gilead Sciences  Gilead Sciences (GILD) Chairman and CEO Daniel O’Day, said, “Gilead’s third-quarter results are …

Anavex Life Sciences: Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial 

November 1, 2024 0

Anavex Life Sciences Anavex Life Sciences (AVXL) presented new data from the Phase IIb/III study showing …

Iterum Therapeutics Receives US FDA Approval of ORLYNVAH™ for the Treatment of Uncomplicated Urinary Tract Infections

October 29, 2024 0

Iterum Therapeutics US FDA Approval On October 25, 2024, Iterum Therapeutics (ITRM) announced that the U.S. …

Some Stories To Know About Vera and Viking Therapeutics

October 29, 2024 0

Vera Therapeutics and Viking Therapeutics Today, October 29, the market stocks’ prices moved south, including good …

Vera Therapeutics Announces Long-Term Improvement Results in Treating Berger’s Nephritis

October 28, 2024 0

Vera Therapeutics Announcement Two days ago, Vera Therapeutics, Inc. (VERA) announced data from its ORIGIN Phase …

Intellia Therapeutics: Positive Results from NTLA-2002 in CRISPR Gene Editing Treatment for Hereditary Angioedema

October 25, 2024 0

Intellia Therapeutics Intellia Therapeutics (NTLA) is a clinical-stage gene editing company focused on revolutionizing medicine with …

The United States FDA Approved Astellas’ product VYLOY in Combination with Fluoropyrimidine and Platinum-Containing Chemotherapy for the First-Line Treatment of Adults with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

October 21, 2024 0

Astellas Pharma Inc Announcement Tokyo, Oct. 18, 2024, Astellas Pharma Inc. (TSE: 4503, President and CEO: …

Vertex Pharmaceuticals to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the ASA Annual Meeting.

October 18, 2024 0

Vertex Pharmaceuticals Announcement October 18, 2024, Vertex Pharmaceuticals  (VRTX) today announced that the company will present …

U.S. FDA Approves AbbVie’s VYALEV™ for Adults Living with Advanced Parkinson’s Disease

October 17, 2024 0

AbbVie FDA Approval for VYALEV for Parkinson’s Disease AbbVie (ABBV) announced that the U.S. FDA  approved …

Aligos Therapeutics is on the Way to Treating MASH and More

October 16, 2024 0

Aligos Therapeutics On September 20, 2024, we posted a press release stating that Aligos Therapeutics (ALGS) …